Current Document Type: HighlightsVideoPage Phase II Results of MonumenTAL-1: Talquetamab for Relapsed/Refractory Multiple Myeloma - JADPRO

Watch More Highlights

Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses the MonumenTAL-1 study of talquetamab in relapsed/refractory multiple myeloma. Pivotal phase II talquetamab data showed > 70% ORR in heavily pretreated patients with RRMM. High response rates were also seen in patients with prior T-cell redirection therapy. The safety profile was clinically manageable, with low rates of high-grade infections and talquetamab discontinuations (Abstract 8036).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.